Suppr超能文献

C反应蛋白/白蛋白比值对非ST段抬高型心肌梗死患者无复流的预测价值

Predictive value of C-reactive protein/albumin ratio for no-reflow in patients with non-ST-elevation myocardial infarction.

作者信息

Rodi Tosu Aydın, Çinar Tufan, Kalyoncuoğlu Muhsin, Biter Halil İbrahim, Çakal Sinem, Çakal Beytullah, Selçuk Murat, Belen Erdal, Mustafa Can Mehmet

机构信息

Department of Cardiology, Haseki Training and Research Hospital, University of Health Sciences, Istanbul, Turkey.

Department of Cardiology, Sultan II. Abdülhamid Han Training and Research Hospital, University of Health Sciences, Istanbul, Turkey.

出版信息

J Cardiovasc Thorac Res. 2022;14(4):214-219. doi: 10.34172/jcvtr.2022.30549. Epub 2022 Nov 22.

Abstract

The focus of this research was to explore the link between CRP (C-reactive protein) /albumin ratio (CAR), a novel inflammatory response marker, and no-reflow (NR) phenomena in non-ST elevation myocardial infarction (non-STEMI) patients during percutaneous coronary intervention (PCI). The current study recruited 209 non-STEMI participants who underwent PCI. The patients were divided into two groups based on their post-intervention Thrombolysis in Myocardial Infarction (TIMI) flow grade; those with and without NR. In all, 30 non-STEMI patients (6.9%) had NR after PCI. CAR values were substantially greater in the NR group. The CAR was identified to be a determinant of the NR (OR: 1.250, 95% CI: 1.033-1.513, =0.02), although CRP and albumin were not independently related with NR in the multivariate analysis. In our investigation, low density lipoprotein-cholesterol levels and high thrombus burden were also predictors of the occurrence of NR. According to receiver operating characteristic curve evaluation, the optimal value of CAR was>1.4 with 60% sensitivity and 47% specificity in detecting NR in non-STEMI patients following PCI. To the best of knowledge, this is the first investigation to demonstrate that the CAR, a new and useful inflammatory marker, can be utilized as a predictor of NR in patients with non-STEMI prior to PCI.

摘要

本研究的重点是探讨一种新型炎症反应标志物C反应蛋白(CRP)/白蛋白比值(CAR)与非ST段抬高型心肌梗死(non-STEMI)患者经皮冠状动脉介入治疗(PCI)期间无复流(NR)现象之间的联系。本研究招募了209例接受PCI的non-STEMI参与者。根据干预后心肌梗死溶栓(TIMI)血流分级将患者分为两组,即有NR和无NR的患者。总共有30例non-STEMI患者(6.9%)在PCI后出现NR。NR组的CAR值显著更高。虽然在多变量分析中CRP和白蛋白与NR无独立相关性,但CAR被确定为NR的一个决定因素(OR:1.250,95%CI:1.033 - 1.513,P = 0.02)。在我们的研究中,低密度脂蛋白胆固醇水平和高血栓负荷也是NR发生的预测因素。根据受试者工作特征曲线评估,CAR的最佳值>1.4,在检测PCI后non-STEMI患者的NR时,敏感性为60%,特异性为47%。据我们所知,这是首次证明CAR这种新的有用炎症标志物可作为non-STEMI患者PCI前NR预测指标的研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c1e/9871161/ae1f51b2063f/jcvtr-14-214-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验